Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Teva's Copaxone progresses toward FDA approval

Aug. 9, 1996

5-HT1A agonist with alpha1-adrenoceptor-blocking properties from Byk Gulden

Aug. 9, 1996

Multiuse melatonergic 3-alkoxybenzylpiperidine derivatives from Bristol-Myers Squibb

Aug. 9, 1996

ADIR describes compunds with high affinity for 5-HT2C and/or 5-HT3C receptors

Aug. 9, 1996

Lidocaine nasal drops shown effective for fast migraine pain relief

Aug. 9, 1996

5-HT1 agonists described by Merck & Co.

Aug. 9, 1996

Actiq to undergo phase III clinical trials

Aug. 9, 1996

Menarini and Lilly sign comarketing agreement

Aug. 9, 1996

Bifemelane claimed for cerebrovascular disorders treatment

July 26, 1996

Research supports role of testosterone in pathogenesis of stroke

July 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.